A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)

NCT07648914 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

446

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: BL-B01D1
DRUG: Albumin-Bound Paclitaxel
DRUG: Paclitaxel
DRUG: Capecitabine

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]